Linezolid Puren (Linezolid)

Linezolid is indicated for several serious bacterial infections affecting the skin, lungs and resistant pathogens.

• Complicated skin and skin structure infections: effective against Gram‑positive bacteria, including MRSA, reducing infection severity and promoting healing.
• Community‑acquired pneumonia: provides coverage for typical and atypical organisms, improving respiratory outcomes.
• Nosocomial pneumonia: active against hospital‑acquired pathogens, including resistant strains, aiding recovery.
• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: offers a treatment option when other agents are ineffective.
• Vancomycin‑resistant Enterococcus (VRE) infections: used as an alternative therapy for infections caused by VRE.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex required for translation. This blockade halts the early stage of peptide chain assembly, resulting in a bacteriostatic effect against susceptible Gram‑positive organisms, including resistant strains such as MRSA and VRE.

Linezolid may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea
• Diarrhea
• Headache
• Metallic taste

Serious or Rare Side Effects

• Thrombocytopenia
• Peripheral neuropathy
• Optic neuropathy
• Serotonin syndrome (when combined with serotonergic agents)

When prescribing linezolid, clinicians should observe several precautionary measures to minimize risks.

• Monitor blood counts: regular CBC testing to detect thrombocytopenia or anemia.
• Assess renal and hepatic function: adjust therapy if significant impairment is present.
• Avoid serotonergic drugs: concurrent use with SSRIs, SNRIs, or MAO inhibitors can precipitate serotonin syndrome.
• Use caution in patients with a history of myelosuppression: evaluate risk before initiating therapy.
• Review dietary tyramine intake: limit high‑tyramine foods to reduce hypertensive reactions.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Linezolid interacts with several medication classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): can cause severe hypertension and serotonin syndrome.
• Serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants, tramadol): risk of serotonin syndrome.
• Sympathomimetic agents (e.g., pseudoephedrine, phenylephrine): may precipitate hypertensive crisis.

Moderate Interactions (Monitor Closely)

• Rifampin: induces hepatic enzymes, reducing linezolid plasma concentrations.
• Warfarin: linezolid may enhance anticoagulant effect, requiring INR monitoring.
• Anticonvulsants (phenytoin, carbamazepine): may lower linezolid levels, necessitating efficacy assessment.